161 Fort Washington AveFl 9New York, NY 10032
Fax+1 212-305-6762
Overview of Dr. Stein
Dr. Mark Stein is an oncologist located in New York, NY, specializing in genitourinary and hematologic oncology. He graduated from New York Medical College in 1998. Currently, he serves as an Associate Professor at both Columbia University Vagelos College of Physicians and Surgeons and Rutgers RWJ Cancer Institute of New Jersey. Dr. Stein is experienced in cancer-associated retinopathy, immunotherapy, genitourinary cancer, pharmacology, and developmental therapeutics. His published work includes studies on metastatic prostate cancer, bladder cancer, and immunotherapy strategies. He has participated in clinical trials related to metastatic castration-resistant prostate cancer. Additionally, he received the CMS Meaningful Use Stage 1 Certification from the ARIA oncology information system in 2013-2014.
Education & Training
New York Medical CollegeClass of 1998
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2004 - 2027
NY State Medical License 1999 - 2027
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2013-2014
Clinical Trials
- Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration Start of enrollment: 2009 Jun 01
- A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. Start of enrollment: 2023 Sep 20
Roles: Contact
Publications & Presentations
PubMed
- Treatments on the Horizon for Men with Advanced Prostate Cancer.Matthew I Ehrlich, Ron S Gejman, Ezra Bernstein, Mark N Stein
The Urologic Clinics of North America. 2026-05-01 - 7 citationsTrial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.Andrew J Armstrong, Michael J Morris, Wassim Abida, Rahul R Aggarwal, Emmanuel S Antonarakis
Journal of Clinical Oncology. 2026-05-01 - Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial.Casey R Ager, Aleksandar Obradovic, Patrick McCann, Matthew Chaimowitz, Alexander L E Wang
Cell Reports. Medicine. 2026-03-17
Press Mentions
Common Diabetes Drug Metformin Really Can Fight Certain CancersNovember 10th, 2023- Can Metformin Delay Progression of Prostate Cancer? Study Provides InsightsNovember 11th, 2023
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
